货号:A237914
同义名:
GM6001; Galardin
Ilomastat(GM6001) 是一种高效的广谱基质金属蛋白酶 (MMP) 抑制剂,对 MMP-1、MMP-2、MMP-3 和 MMP-9 的 IC50 值分别为 1.5 nM、1.1 nM、1.9 nM 和 0.5 nM,对人皮肤成纤维细胞胶原酶 (MMP-1) 的 Ki 为 0.4 nM。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | MMP ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marimastat |
+++
MMP-14, IC50: 3 nM MMP-7, IC50: 16 nM |
98% | |||||||||||||||||
| Ilomastat |
++++
MMP-2, Ki: 0.1 nM MMP-26, Ki: 0.36 nM |
99%+ | |||||||||||||||||
| SB-3CT |
+
MMP-2, Ki: 13.9 nM MMP-9, Ki: 600 nM |
99%+ | |||||||||||||||||
| Doxycycline | ✔ | 95% | |||||||||||||||||
| NSC 405020 | ✔ | 98% | |||||||||||||||||
| Batimastat |
+++
MMP-1, IC50: 3 nM MMP-7, IC50: 4 nM |
99%+ | |||||||||||||||||
| Nobiletin | ✔ | 99% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | GM 6001 is a broad spectrum MMP inhibitor with Ki values of 0.1nM, 0.2nM, 0.36nM, 0.4nM, 0.5nM, 3.6nM and 3.7nM for MMP-8, MMP-9, MMP-26, MMP-1, MMP-2, MMP-12 and MMP-7[1]. The tyrosine phosphorylation of EGFR induced by leptin could be significantly attenuated by treatment with 25μM GM6001 for 30min in rat aortic smooth muscle cells, due to the inhibition of proteolytic cleavage of transmembrane precursors via matrix metalloproteinase by GM6001[2]. Inhibition of MMP-2/MMP-9-mediated NCAM (Neural cell adhesion molecule) proteolysis by administration of 5μg GM6001 through intracerebroventricular route 30 minutes before and 2 h after ischemia attenuated the infarction, behavioral abnormalities of MCAO (middle cerebral artery occlusion) model mice, with suppression on the level of NCAM cleavage product by GM6001 observed[3]. |
| Concentration | Treated Time | Description | References | |
| U87 glioblastoma cells | 10 µM | 24 hours | Increased An2 internalization | Int J Mol Sci. 2022 Nov 17;23(22):14214 |
| Ly6G+ neutrophils | 50 µM | 8 hours | To evaluate the effect of Ilomastat on the migration ability of Ly6G+ neutrophils from leukemic mice. Results showed that Ilomastat significantly inhibited the migration ability of neutrophils from leukemic mice, while having no effect on neutrophils from naive mice. | Exp Hematol Oncol. 2024 May 10;13(1):49 |
| C6 glioma cells | 0, 25, 50, 75, or 100 μM | 24 hours | To evaluate the inhibitory effect of Ilomastat on MMP3 activity secreted by C6-Cx43 cells. Results showed that Ilomastat inhibited MMP3 activity in a concentration-dependent manner. | J Enzyme Inhib Med Chem. 2020 Dec;35(1):672-681 |
| juvenile equine tendon and ligament myofibroblasts | 10 µg/mL and 20 µg/mL | 24 hours | To evaluate the effect of Ilomastat on the viability and proliferation capacity of juvenile equine tendon and ligament myofibroblasts. Results showed no significant negative impact on cell viability and proliferation at the tested concentrations. | Sci Rep. 2025 May 6;15(1):15762 |
| HrasA5 cells | 10 µM | 3 weeks | Inhibition of MMP activity prevented invasive growth of HrasA5 cells | Front Oncol. 2022 Jan 31;12:827985 |
| Human Tenon fibroblast cells (HTFs) | 0.01, 1, 10, 100 μM | 7 days | To evaluate the inhibitory effect of Ilomastat-CD on collagen gel contraction. Results showed that Ilomastat-CD significantly inhibited collagen gel contraction at concentrations ranging from 1 to 100 μM, similar to uncomplexed Ilomastat. | Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3425-3431 |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | FGFR1-driven leukemia model | Intraperitoneal injection | 100 mg/kg | 7 consecutive days | To evaluate the effect of Ilomastat on survival and immune cell composition in leukemic mice. Results showed that Ilomastat treatment significantly prolonged survival of leukemic mice, reduced leukemic cells and PMN-MDSCs in peripheral blood, and increased T-cell levels. | Exp Hematol Oncol. 2024 May 10;13(1):49 |
| Mice | CFTR knockout mice | Intratracheal administration | 50 µM and 150 µM | Single dose, monitored at 4, 24, and 48 hours | Evaluate the effect of Ilomastat on lung inflammation; results showed 150 μM Ilomastat significantly reduced inflammation in CF mice | Virulence. 2018;9(1):1008-1018 |
| New Zealand White rabbits | Topical eye drop | 100 μL (1 mg/mL) | Single dose, sampled after 4 hours | To assess the distribution of Ilomastat-CD in ocular tissues. Results showed therapeutic concentrations of Ilomastat in sclera, conjunctiva, and aqueous humor. | Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3425-3431 | |
| C57BL/6J wild-type and CFTR knockout mice | Acute lung infection model | Intratracheal administration | 150 µM | Administered 20 hours post-infection, monitored at 4 and 24 hours | To evaluate the anti-inflammatory effects of Ilomastat in acute P. aeruginosa lung infection. Results showed that Ilomastat reduced IL-8-dependent bioluminescence signal, indicating reduced inflammation. | Clin Exp Immunol. 2021 Jan;203(1):87-95 |
| New Zealand white rabbits | Experimental glaucoma filtration surgery model | Subconjunctival injection | 100 μM | Single injection, lasted for 28 days | To evaluate the safety of Ilomastat in glaucoma filtration surgery, results showed that Ilomastat had less toxicity on rabbit cornea, conjunctiva, and ciliary body compared to MMC. | J Korean Med Sci. 2017 Apr;32(4):666-671 |
| Dose | Hamster: 20 mg/kg[4] (i.p.) Rat: 1.2 mg/kg[5] (i.p.); 50 mg/kg, 100 mg/kg[6] (i.p.) |
| Administration | i.p. |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03297827 | - | Recruiting | August 27, 2019 | United States, New Mexico ... 展开 >> Department of Neurology, University of New Mexico Recruiting Albuquerque, New Mexico, United States, 87131-0007 Contact: Asad Ikram, MD 505-272-9382 aikram@salud.unm.edu Principal Investigator: Atif Zafar, MD Sub-Investigator: Asad Ikram, MD 收起 << |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.57mL 0.51mL 0.26mL |
12.87mL 2.57mL 1.29mL |
25.74mL 5.15mL 2.57mL |
|
| CAS号 | 142880-36-2 |
| 分子式 | C20H28N4O4 |
| 分子量 | 388.46 |
| SMILES Code | O=C(N[C@@H](CC1=CNC2=C1C=CC=C2)C(NC)=O)[C@H](CC(C)C)CC(NO)=O |
| MDL No. | MFCD00917040 |
| 别名 | GM6001; Galardin |
| 运输 | 蓝冰 |
| InChI Key | NITYDPDXAAFEIT-DYVFJYSZSA-N |
| Pubchem ID | 132519 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, 2-8°C |
| 溶解方案 |
DMSO: 45 mg/mL(115.84 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1